GL1X · GenesisL1 explorer

Research workbench

Human endothelial nitric oxide synthase with 6- nitroindazole bound

Analyse Human endothelial nitric oxide synthase with 6- nitroindazole bound in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
1M9M
Type
protein
Length
800 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Endothelial nitric-oxide synthase
EC
1.14.13.39
UniProt
P29474
Ligands
HEM, 6NI, ZN, NA
Pockets
8 · best druggability 0.85

Structure

x-ray diffraction · 1 distinct chain · 41% helix, 16% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, BEndothelial nitric-oxide synthase (EC 1.14.13.39)protein40041% helix, 16% strandP29474

Ligands and binding sites

  • HEM · Protoporphyrin IX containing Fe · ligand · 2 copies · chains A, B
  • 6NI · 6-nitroindazole · ligand · 2 copies · chains A, B
  • ZN · Zinc ion · metal · chains A, B
  • NA · Sodium ion · metal · chains A
  • IPA · Isopropyl alcohol · additive · 3 copies · chains A, B
  • MPD · (4S)-2-methyl-2,4-pentanediol · additive · 3 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

8 pockets found on a 1 Å grid, 5 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
110220.850.8686NA, HEM, 6NI, MPD
211790.830.8482MPD, HEM, 6NI, IPA
3970.720.9422IPA
4920.550.8519empty
51020.530.8321empty

Interfaces

1 interface between chains.

  • A–B · 2610 Ų buried · 37 hydrogen bonds · protein-protein

Compared structures

  • 1M9M · human endothelial nitric oxide synthase with 6-nitroindazole bound · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.